Angiolutions announces advisory board to accelerate early-stage treatment for abdominal aortic aneurysms
Composed of leading experts from medicine, research & industry
Aims to accelerate the clinical testing and market launch of Angiolutions’ early aneurysm treatment
Share this on:
July 3, 2024 – Angiolutions announces its Advisory Board, comprising industry leaders, distinguished researchers, and clinicians from world-renowned institutions. Each member brings unique expertise to advance Angiolutions’ mission of delivering the first implant designed to stop abdominal aortic aneurysms at an early stage to patients.
Meet the Angiolutions Advisory Board!
Prof. Dr. med. Hubert Schelzig
"Our experienced and diverse board constantly challenges and inspires us. This helps us to accelerate our efforts to bring the first implant to stop early-stage abdominal aortic aneurysms to market."
About Angiolutions
Angiolutions revolutionizes the treatment of life-threatening abdominal aortic aneurysms (AAAs) with a first-of-its-kind medical device that stops AAA growth at an early stage. AAA is a progressive dilation of the biggest blood vessel of our body affecting 1 in 20 people. By treating early-stage AAA, Angiolutions brings new hope to hundreds of thousands of patients that are currently without a treatment option.
